{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:29:33Z","timestamp":1789010973931,"version":"build-2803163510"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.28373","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T16:41:04Z","timestamp":1634834464000},"page":"e2128373","source":"Crossref","is-referenced-by-count":22,"title":["Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Angie Mae","family":"Rodday","sequence":"first","affiliation":[{"name":"Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Hahn","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita J.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Lindenauer","sequence":"additional","affiliation":[{"name":"Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School Baystate, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"6","key":"zoi210824r1","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"3","key":"zoi210824r3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"5","key":"zoi210824r4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/CCO.0b013e328348c6c1","article-title":"How we treat elderly patients with Hodgkin lymphoma.","volume":"23","author":"Bj\u00f6rkholm","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"12","key":"zoi210824r5","first-page":"1369","article-title":"Hodgkin lymphoma in older patients: an uncommon disease in need of study.","volume":"22","author":"Evens","year":"2008","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"zoi210824r7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2070","article-title":"Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes.","volume":"31","author":"Jagadeesh","year":"2013","journal-title":"Hematol Oncol"},{"issue":"1","key":"zoi210824r8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.15652","article-title":"The treatment of older Hodgkin lymphoma patients.","volume":"184","author":"B\u00f6ll","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"zoi210824r9","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/10428190500518602","article-title":"Hodgkin\u2019s lymphoma in the elderly: the results of 10 years of follow-up.","volume":"47","author":"Feltl","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"zoi210824r11","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group.","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi210824r12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.v190.2","article-title":"First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)\u2013Medicare population-based study.","volume":"190","author":"Rodday","year":"2020","journal-title":"Br J Haematol"},{"issue":"18","key":"zoi210824r13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1001\/jama.2019.17016","article-title":"Older patients (still) left out of cancer clinical trials.","volume":"322","author":"Abbasi","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"zoi210824r14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi210824r15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin\u2019s lymphoma patients: results from an Intergruppo Italiano Linfomi (IIL) study.","volume":"15","author":"Levis","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi210824r16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.2013.161.issue-1","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"24","key":"zoi210824r17","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"issue":"1","key":"zoi210824r18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi210824r19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.6004\/jnccn.2012.0061","article-title":"Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.","volume":"10","author":"Hoppe","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"zoi210824r20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bjh.2015.170.issue-2","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"zoi210824r21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cam4.2016.5.issue-6","article-title":"Improved survival time trends in Hodgkin\u2019s lymphoma.","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"issue":"8","key":"zoi210824r22","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/MLR.0000000000000561","article-title":"Racial\/ethnic and socioeconomic differences in colorectal and breast cancer treatment quality: the role of physician-level variations in care.","volume":"54","author":"Popescu","year":"2016","journal-title":"Med Care"},{"issue":"7","key":"zoi210824r23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","article-title":"Development of a claims-based frailty indicator anchored to a well-established frailty phenotype.","volume":"55","author":"Segal","year":"2017","journal-title":"Med Care"},{"issue":"11","key":"zoi210824r24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"19","key":"zoi210824r25","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma.","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210824r29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point.","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"11","key":"zoi210824r30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response.","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi210824r31","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.jclinepi.2013.01.014","article-title":"Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators.","volume":"66","author":"Mi","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi210824r32","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Tutorial in biostatistics: competing risks and multi-state models.","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"19","key":"zoi210824r33","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"19","key":"zoi210824r34","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models.","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"4","key":"zoi210824r36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi210824r37","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values.","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"7","key":"zoi210824r39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.21037\/atm","article-title":"Time-varying covariates and coefficients in Cox regression models.","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"issue":"6","key":"zoi210824r40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.13904","article-title":"Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).","volume":"172","author":"Zallio","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"zoi210824r41","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","article-title":"Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry.","volume":"41","author":"van Spronsen","year":"2005","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi210824r42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1200\/JCO.2014.55.3107","article-title":"Receipt of chemotherapy among Medicare patients with cancer by type of supplemental insurance.","volume":"33","author":"Warren","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi210824r43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Geographic access to cancer care in the U.S.","volume":"112","author":"Onega","year":"2008","journal-title":"Cancer"},{"issue":"19","key":"zoi210824r44","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1002\/cncr.v121.19","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma.","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"issue":"21","key":"zoi210824r45","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease: International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease.","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi210824r46","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"issue":"3","key":"zoi210824r47","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jgo.2020.08.001","article-title":"Shared decision-making in older patients with cancer: what does the patient want?","volume":"12","author":"Rostoft","year":"2021","journal-title":"J Geriatr Onco"},{"issue":"9","key":"zoi210824r48","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study.","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"zoi210824r49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jgo.2014.03.001","article-title":"Feasibility of geriatric assessment in community oncology clinics.","volume":"5","author":"Williams","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"zoi210824r50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","article-title":"Frailty and the management of hematologic malignancies.","volume":"131","author":"Abel","year":"2018","journal-title":"Blood"},{"issue":"2","key":"zoi210824r51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjh.2019.184.issue-2","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.","volume":"184","author":"Br\u00f6ckelmann","year":"2019","journal-title":"Br J Haematol"},{"issue":"19","key":"zoi210824r52","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma.","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi210824r53","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/jnci\/djq393","article-title":"Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.","volume":"102","author":"Hadley","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi210824r54","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhealeco.2007.09.009","article-title":"Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling.","volume":"27","author":"Terza","year":"2008","journal-title":"J Health Econ"},{"issue":"8","key":"zoi210824r56","first-page":"3","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"issue":"22","key":"zoi210824r57","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1056\/NEJMhpr1804089","article-title":"Medicare Advantage checkup.","volume":"379","author":"Neuman","year":"2018","journal-title":"N Engl J Med"},{"key":"zoi210824r28","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"zoi210824r55","volume-title":"The Dartmouth Atlas of Health Care","author":"The Center for the Evaluative Clinical Sciences DMS","year":"2008"},{"key":"zoi210824r2","unstructured":"National Cancer Institute. SEER cancer statistics review 1975-2017: Hodgkin lymphoma. Accessed December 10, 2020. https:\/\/seer.cancer.gov\/csr\/1975_2017\/browse_csr.php?sectionSEL=9&pageSEL=sect_09_table.08"},{"key":"zoi210824r6","unstructured":"Reagan? PM, Magnuson? A, Friedberg? JW. Hodgkin lymphoma in older patients.? Am J Hematol Oncol. 2016;12(7):13-19. Accessed September 16, 2021. https:\/\/www.gotoper.com\/publications\/ajho\/2016\/2016july\/hodgkin-lymphoma-in-older-patients"},{"key":"zoi210824r10","unstructured":"Clinical Practice Guidelines in Oncology. Hodgkin lymphoma: NCCN evidence blocks\u2014version 1.2019. Accessed August 7, 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkin_blocks.pdf"},{"key":"zoi210824r26","unstructured":"Health Resources & Services Administration. Area health resources files. Updated July 31, 2020. Accessed June 12, 2020. https:\/\/data.hrsa.gov\/topics\/health-workforce\/ahrf"},{"key":"zoi210824r27","unstructured":"Research Data Assistance Center. CMS cell size suppression policy. Updated May 8, 2017. Accessed January 2, 2020. https:\/\/www.resdac.org\/articles\/cms-cell-size-suppression-policy"},{"key":"zoi210824r35","unstructured":"McCaffrey? DF, Burgette? LF, Griffin? BA, Martin? C. Propensity scores for multiple treatments: a tutorial for the MNPS macro in the TWANG SAS macros. RAND Corporation. Updated June 16, 2016. Accessed June 1, 2020. https:\/\/www.rand.org\/pubs\/tools\/TL169z1.html"},{"key":"zoi210824r38","unstructured":"Mathur? M, Ding? P, Riddell? C, Simith? L, VanderWeele? T. E-value calculator. Accessed October 19, 2020. https:\/\/www.evalue-calculator.com\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2785328\/rodday_2021_oi_210824_1634154078.83621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T16:41:14Z","timestamp":1634834474000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2785328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28373","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}